The MedInsight Research Institute, a non-profit organization dedicated to educating patients and physicians about non-commercially sponsored treatments for chronic and serious medical conditions, has launched a revamped LDN information website at LDNscience.org.
LDN, an acronym for low dose naltrexone, is the biggest patient-initiated drug discovery program in history. LDN involves using an FDA-approved opiate addiction treatment drug, naltrexone, at a very low dose to induce significant medical benefits among patients suffering from autoimmune diseases and other chronic medical conditions. A series of clinical trials has shown LDN to be useful for the treatment of Crohn's disease, multiple sclerosis (MS), fibromyalgia, HIV, Parkinson's and chronic pain. These studies have been carried out at major academic institutions including Penn State University, Stanford University, the University of California San Francisco, and SUNY Buffalo, among others.
After MedInsight initiated the first-ever clinical trial of LDN in patients with Crohn's disease, 13 additional clinical trials and 19 case reports about LDN have been published in medical literature to date.
"This is clear evidence of the great power consumers wield once we take responsibility for our own healthcare choices, and proceed to drive the changes we wish to see in medical research and practice. The success of LDN is a model for the kind of great patient-initiated advances that are possible," said Moshe Rogosnitzky, founder of LDNscience.org. "We are pleased to offer an even better resource for patients, families, doctors and researchers who are passionate about treating these serious conditions and enhancing quality of life."
LDNscience includes all the research to date about LDN, explanatory material for patients and doctors, a directory of doctors prescribing LDN, an FAQ section, interviews with LDN researchers and LDN users, and more.
"LDN is an unparalleled example of what consumer power and initiative can achieve. LDN offers hope for those who have failed standard therapies or find standard therapies too risky," Rogosnitzky added. "It is astounding that a pharmaceutical treatment with no commercial backing whatsoever has managed to reach 300,000 patients across the globe, despite not being approved yet by the health authorities in any country."
"We are grateful that LDNscience has played such a major role in educating consumers and physicians about a very safe therapy that has helped turn so many patients' lives around," said Shira Bienstock, content director at LDNscience. "Through our remodeled website and other projects in the pipeline, we look forward to contributing even more to the worldwide community regarding advances in low dose naltrexone research."
###
About LDNscience: LDNscience® is a public information project of the MedInsight Research Institute http://www.ldnscience.org
About MedInsight: MedInsight Research Institute is a U.S./ U.K.-based non-profit organization established in 2006 that serves as a platform for researching and indexing non-commercial off-label (repurposed) treatments for cancer and chronic diseases.
Media Contact
Shira Bienstock
shira@medinsight.org
